JO
INO icon

John Overdeck’s Inovio Pharmaceuticals INO Stock Holding History

John Overdeck’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
1,239,778
+849,394
+218% +$1.01M ﹤0.01% 3360
2026
Q1 		$679K Buy
390,384
+67,645
+21% +$111K ﹤0.01% 3521
2025
Q4 		$562K Buy
322,739
+31,939
+11% +$70.4K ﹤0.01% 3241
2025
Q3 		$680K Buy
290,800
+218,073
+300% +$418K ﹤0.01% 2826
2025
Q2 		$148K Buy
72,727
+363
+0.5% +$696 ﹤0.01% 2958
2025
Q1 		$118K Buy
+72,364
New +$145K ﹤0.01% 2944
2024
Q4 		– Sell
-23,195
Closed -$134K – 3339
2024
Q3 		$134K Sell
23,195
-14,403
-38% -$119K ﹤0.01% 2856
2024
Q2 		$304K Buy
37,598
+17,337
+86% +$182K ﹤0.01% 2590
2024
Q1 		$281K Sell
20,261
-7,163
-26% -$61.8K ﹤0.01% 2584
2023
Q4 		$168K Sell
27,424
-41,679
-60% -$206K ﹤0.01% 2874
2023
Q3 		$323K Sell
69,103
-80,750
-54% -$446K ﹤0.01% 2463
2023
Q2 		$803K Buy
+149,853
New +$1.21M ﹤0.01% 2074
2023
Q1 		– Sell
-35,210
Closed -$659K – 3074
2022
Q4 		$659K Sell
35,210
-122,990
-78% -$2.79M ﹤0.01% 1903
2022
Q3 		$3.27M Sell
158,200
-223,436
-59% -$5.72M 0.01% 937
2022
Q2 		$7.92M Buy
381,636
+186,768
+96% +$5.26M 0.03% 589
2022
Q1 		$8.39M Buy
+194,868
New +$8.78M 0.02% 677
2020
Q1 		– Sell
-12,751
Closed -$505K – 3449
2019
Q4 		$505K Buy
12,751
+11,366
+821% +$342K ﹤0.01% 2792
2019
Q3 		$34K Sell
1,385
-8,730
-86% -$265K ﹤0.01% 3373
2019
Q2 		$357K Sell
10,115
-1,082
-10% -$43K ﹤0.01% 2748
2019
Q1 		$501K Sell
11,197
-3,391
-23% -$171K ﹤0.01% 2271
2018
Q4 		$700K Buy
14,588
+2,048
+16% +$124K ﹤0.01% 1876
2018
Q3 		$837K Buy
12,540
+10,446
+499% +$582K ﹤0.01% 2111
2018
Q2 		$98K Buy
+2,094
New +$115K ﹤0.01% 3207

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

John Overdeck's INO Position: Q2 2026 in Review

John Overdeck increased its Inovio Pharmaceuticals (INO) stake by 218% in Q2 2026, buying an estimated $1.01M and bringing the position to 1,239,778 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3360.

John Overdeck first reported a position in INO in Q2 2018 and has held it in 23 quarters since. The position peaked at $8.39M in Q1 2022. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • John Overdeck held 1,239,778 shares of Inovio Pharmaceuticals worth $1.36M as of Q2 2026.
  • John Overdeck bought 849,394 Inovio Pharmaceuticals shares in Q2 2026, an estimated $1.01M.
  • Inovio Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3360 holding.
  • John Overdeck first reported a position in Inovio Pharmaceuticals in Q2 2018 and has held it in 23 quarters since.
  • John Overdeck's Inovio Pharmaceuticals position peaked at $8.39M in Q1 2022.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.